Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.

Scientific reports - 11 Mar 2021

Hasenfratz Marc, Mellert Kevin, Marienfeld Ralf, von Baer Alexandra, Schultheiss Markus, Roitman P D, Aponte-Tinao L A, Lehner Burkhard, Möller Peter, Mechtersheimer Gunhild, Barth Thomas F E

Abstract excerpt

Giant cell tumor of bone (GCTB) is a locally aggressive lesion of intermediate malignancy. Malignant transformation of GCTB is a rare event. In 2013, the humanized monoclonal antibody against receptor activator of nuclear factor-κb-Ligand (RANKL) denosumab was approved for treatment of advanced GCTB. Since then, several reports have questioned the role of denosumab during occasional malignant transformation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Neoplastic
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatal Outcome

Share to Histones

Share to Mutation

Share to Polymorphism, Single Nucleotide

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 33707617
DOI: 10.1038/s41598-021-85319-x
PMCID: PMC7952552

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.PMID 33707617Read ↗

Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.Semantic proximity Read ↗

Giant cell tumor of bone with H3F3B mutation: A case report.Semantic proximity Read ↗

Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.Semantic proximity Read ↗

Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of boneSemantic proximity Read ↗

H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases.Semantic proximity Read ↗

Drivers underpinning the malignant transformation of giant cell tumour of boneSemantic proximity Read ↗

Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of BoneSemantic proximity Read ↗

Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.Semantic proximity Read ↗

H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.Semantic proximity Read ↗

Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimicsSemantic proximity Read ↗

Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of boneSemantic proximity Read ↗

An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.